Ubiquitin-like modifier activating enzyme 2 (UBA2) is also known as small ubiquitin-like modifier (SUMO)-activating enzyme subunit 2 (SAE2). The UBA2 gene is present on human chromosome 19q13.11. It has three domains: an adenylation, catalytic and an ubiquitin-like domain.
Synonyms: Anti-ARX; Anti-FLJ13058; Anti-HRIHFB2115; Anti-SAE2
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: Ubiquitin-like modifier activating enzyme 2 (UBA2) participates in the sumoylation pathway. UBA2 mediated small ubiquitin-like modifier (SUMO) conjugation may play an important role in regulating the dynamics of cell cycle events. Deletion of UBA2 gene is associated with ectodermal and cutis aplasia. Microdeletion near the UBA2 gene locus is implicated in ectrodactyly ectodermal dysplasia??clefting (EEC) syndrome.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC